Ann: Appendix 4C - quarterly, page-37

If the decision to walk away from a partnership deal means that the majority of the value from the program is not lost to Celgene, then Silvui has done us shareholders a great favour and the on market raisings are a small price to pay in the grand scheme of things.
This, among us commoners n folk is called "not selling yourself short".

Sure.
Assuming that's what happened.

And in the absence of any evidence to suggest that it has, it's tantamount to speculating.


"Drawing this conclusion is of course dependent on Silvui's ability to enter into a more favourable deal down the track, and it starts with MNK."

Well, here we don't need to rely on speculation, because we have publicly-available information to inform our views, and that information is the latest financial statements of Celgene and Mallinkrodt, which show the former being an absolute financial powerhouse and the latter being financially challenged (to put it mildly).

Meaning that the probability of the favourable deal - given the financial health of the prospective partner would be an important criterion - would have been much, much higher in Celgene's case, than Mallinkrodt's.